Search Results
75 Results Found for “cancer vaccines”
Professor Pamela Kearns discusses the key points from her Plenary presentation on how the ITCC is expanding access to innovative therapies, harnessing precision data and reshaping Europe’s paediatric oncology clinical trial landscape. “We want to bring innovation directly to ...
Pancreatic cancer (PC) is the tenth most common cancer in 2024, with 66,440 new cases and 51,570 deaths.1,2 Globally, the prevalence varies from 10/100,000 cases in the Americas and Europe to 0.9/100,000 cases in South Central Asia and most of Africa.3 Currently, it has the ...
The European Cancer Summit 2025 brought together leaders from across oncology to assess progress under Europe’s Beating Cancer Plan and chart next steps. Sessions focused on accelerating HPV elimination, strengthening screening and prevention policies, and preparing health systems for the rapid rise of artificial intelligence. Speakers emphasised practical solutions, collaborative action and the need for sustained investment to ensure equitable, high-quality cancer care across Europe.
Dr Rimas Lukas highlights early-stage neuro-oncology research presented at ANA 2025. Key approaches targeting CNS tumours include immune checkpoint inhibition, patient-derived glioblastoma vaccines, focused ultrasound, and cGAS–STING pathway therapies. The session showcased innovative strategies aiming to harness immunity in the fight against these difficult-to-treat cancers.
Cancer is a leading cause of death worldwide and represents a growing major public health problem. Every year on February 4, World Cancer Day serves as a global initiative to raise awareness, promote education, and drive action in the fight against ...
The COVID-19 pandemic accelerated the development of mRNA technologies, most notably with the creation of mRNA vaccines targeting SARS-CoV-2. While these vaccines helped control the pandemic, their potential may extend beyond infectious diseases, with growing interest in their potential application ...
We’re thrilled to welcome Dr. Ken Kato (National Cancer Center Hospital, Tokyo, Japan) to discuss the unique advantages and challenges of conducting cancer research in Japan. Key advantages include robust regulatory support, streamlined trial approvals and strong collaboration with ...
The field of immuno-oncology has provided novel therapeutic agents that have led to significant improvements in patient outcomes across many tumour types. There have also been great efforts to incorporate immunotherapy (IO) into the treatment paradigms of gastrointestinal (GI) cancers. ...
Treatment options for myeloma have rapidly expanded in the past decade and, as with many cancers, the number of oral drug options has increased considerably. Given the more limited number of cancer hospitals, patients often must travel considerable distance to ...
Cervical cancer (CC) remains one of the most frequent cancers in women, representing the fourth cause of neoplasia in women in terms of incidence, and has a high lethality rate.1 Indeed, worldwide 341,831 women die each year because of this disease, ...
The antitumor activity of immune checkpoint inhibotors in various solid and haematologic malignancies has substantially increased immunotherapy implications for cancer. Once only a niche treatment for selected cancers (renal cancer and melanoma), now cancer immunotherapy has become an important option ...
Advanced age and other comorbid conditions put patients with chronic lymphocytic leukaemia (CLL) at an increased risk of morbidity and mortality from SARS-CoV-2 infection, with early studies showing case fatality rates of over 30% in patients with CLL with symptomatic COVID-19.1,2 ...
Prostate cancer is the second most common cause of cancer mortality in men, with most deaths occurring as a result of metastatic disease that has become resistant to androgen deprivation therapy (ADT).1 Most recently, immunotherapy, in the form of immune ...
Pancreatic ductal adenocarcinoma (PDA) is predicted to beat colon cancer in terms of total cancer-related deaths in the USA by this year (2020).1 Given this projected burden of disease, efforts in understanding and developing new treatments for PDA are paramount. In ...
“It is difficult to evaluate what did not happen.” – Academician, LV Gromashevsky The COVID-19 pandemic may be considered the first global health catastrophe in the past 100 years, since it has affected not only economic, political and medical paradigms, but also ...
Dear friends and colleagues in the SIOP Europe Community, We are all currently facing difficult challenges and stresses, both personal and professional, in the unprecedented circumstances of the COVID-19 pandemic. As we are now several weeks into the pandemic reaching ...
Craig E Devoe1 and Wadie F Bahou2 Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, USA Stony Brook University Medical Center, Stony Brook, NY, USA Q. What is the current outlook on the effect ...
Advanced (locally advanced/unresectable or metastatic) urothelial cancer (UC) is an incurable disease with a poor prognosis.1 Platinum-based chemotherapy is the first-line treatment for most patients and, until recently, patients with advanced UC that has progressed after platinum-based chemotherapy had ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
